Active substanceTramadolTramadol
Similar drugsTo uncover
  • Tramadol
    capsules inwards 
    OZONE, LLC     Russia
  • Tramadol
    solution for injections 
  • Tramadol
    pills inwards 
    PRANAFARM, LLC     Russia
  • Tramadol
    pills inwards 
    OZONE, LLC     Russia
  • Tramadol
    solution for injections 
    Hemofarm AD     Serbia
  • Tramadol
    capsules inwards 
    Hemofarm AD     Serbia
  • Tramadol
    solution for injections 
  • Tramadol
    suppositories rect. 
    HEXAL AG     Germany
  • Tramadol
    solution for injections 
    HEXAL AG     Germany
  • Tramadol
    pills inwards 
    HEXAL AG     Germany
  • Tramadol
    capsules inwards 
    HEXAL AG     Germany
  • Tramadol
    solution for injections 
  • Tramadol
    pills inwards 
    ORGANICS, JSC     Russia
  • Tramadol
    solution for injections 
    ORGANICS, JSC     Russia
  • Tramadol
    solution for injections 
    BRYNTSALOV-A, CJSC     Russia
  • Tramadol
    capsules inwards 
  • Tramadol
    drops inwards 
  • Tramadol
    suppositories rect. 
  • Tramadol retard
    pills inwards 
  • Tramadol STADA®
    capsules inwards 
  • Tramadol-Acry®
    capsules inwards 
    AKRIKHIN HFK, JSC     Russia
  • Tramadol-GR
    solution for injections 
  • Tramadol-GR
    solution for injections 
  • Tramadol-Plekhiko
    solution for injections 
  • Tramaclosydol®
    pills inwards 
    Laboratorios Bago S.A.     Argentina
  • Tramaclosydol®
    solution for injections 
    Laboratorios Bago S.A.     Argentina
  • Tramal®
    solution for injections 
  • Tramal®
    suppositories rect. 
  • Tramal®
    drops inwards 
    Grünenthal GmbH     Germany
  • Tramal®
    capsules inwards 
  • Tramal®ardard
    pills inwards 
  • Tramolin®
    solution for injections 
    BRYNTSALOV-A, CJSC     Russia
  • Dosage form: & nbspPills.
    Composition:
    1 tablet contains:
    active substance: tramadol hydrochloride - 50 mg;
    Excipients: lactose 15.0 mg; microcrystalline cellulose - 101.00 mg; magnesium stearate - 1.00 mg; crospovidone - 12.50 mg; Macrogol 4000 - 2.00 mg; saccharin sodium - 15.00 mg; silicon colloidal oxide - 1.00 mg; flavoring - 22.5 mg.
    Description:Round, flat, white with hardly noticeable impregnations, slightly scabrous tablets with a characteristic smell of strawberries.
    Pharmacotherapeutic group:An analgesic with a mixed mechanism of action.
    ATX: & nbsp

    N.02.A.X.02   Tramadol

    Pharmacodynamics:Tramadol - opioid synthetic analgesic, which has a central effect. It is a non-selective complete agonist of μ-, δ-, to-opioid receptors, with a great affinity for μ-opioid receptors. The second mechanism of action of tramadol, which enhances its analgesic effect, is the suppression of norepinephrine reuptake by neurons and increased release of serotonin.
    Tramadol also has antitussive action. In therapeutic doses does not depress respiration and practically does not affect the bowel motility. Influence on the cardiovascular system is weakly expressed. Analgesic potential of tramadol is 1 / 10-1 / 6 of the activity of morphine.
    Pharmacokinetics:

    After oral administration quickly and almost completely absorbed from the gastrointestinal tract (about 90%). Bioavailability with a single oral intake is about 70%, does not depend on simultaneous intake of food and increases with repeated use. The maximum concentration in the blood plasma is determined 2 hours after ingestion. The volume of distribution is 209 liters.Connection with blood plasma proteins - 20%.

    Penetrates through blood-brain and placental barriers. In breast milk, the unchanged drug, along with the O-demethylated derivative, accumulates at very low concentrations (OD% and 0.02%, respectively, of the dose taken).

    In the liver is metabolized by N- and O-demethylation followed by conjugation with glucuronic acid. There were 11 metabolites, of which only mono-O-desmethyltramadol (Ml) has pharmacological activity. The half-life period (T1/2) tramadol - 6 h, (mono-O-desmethyltramadol) - 7.9 h; in patients older than 75 years - 7.4 h (tramadol); in patients with cirrhosis of the liver - 13.3 ± 4.9 h (tramadol), 18.5 ± 9.4 h (mono-Odesselmithramadol), in severe cases - 22.3 h and 36 h, respectively; in patients with chronic renal failure (creatinine clearance less than 10 ml / min) - 11 ± 3.2 h (tramadol), 16.9 ± 3 h (mono-O-desmethyltramadol), in severe cases - 19.5 h and 43.2 h, respectively.

    The linear profile of pharmacokinetics persists with the application of therapeutic doses.

    The concentration of tramadol in the blood plasma and its analgesic effect depend on the dosage, but can vary in individual cases. The effective concentration of tramadol in serum is 100-300 ng / ml.

    Inhibition of cytochrome P450 isoenzymes (CYP3A4 and / or CYP2D6), involved in biotransformation of tramadol, can affect the concentration of tramadol and its active metabolites in blood plasma. So far no clinically relevant interactions have been described.

    Tramadol and its metabolites are excreted kidneys (25 - 35% unchanged), the average cumulative index of renal excretion is 90%. If the kidney or liver is damaged, the half-life period increases slightly. In patients with cirrhosis of the liver, the average half-lives of tramadol and O-demethyl tramadol were 13.3 ± 4.9 hours and 18.5 ± 9.4 hours, respectively, and the extreme values ​​reached 22.3 and 36 hours, respectively. In patients with renal insufficiency (creatinine clearance less than 5 ml / min), the average half-lives of tramadol and O-demethyl tramadol were 11 ± 3.2 hours and 16.9 ± 3 hours, respectively, and the extreme values ​​reached 19.5 and 43, 2 hours, respectively.

    About 7% is output by hemodialysis.

    Indications:
    - pain syndrome of moderate and severe intensity of different etiology (postoperative period, trauma, pain in cancer patients);

    - anesthesia in the conduct of painful diagnostic or therapeutic manipulations.
    Contraindications:
    - hypersensitivity to tramadol or other components of the drug;
    - hypersensitivity to other opioids;
    - acute intoxication with alcohol, hypnotics, analgesics, opioids or other psychotropic drugs;
    - severe renal failure (creatinine clearance less than 10 ml / min);
    - severe hepatic impairment;
    - as a drug for the treatment of the syndrome of "withdrawal" of opioids;
    - simultaneous administration of monoamine oxidase inhibitors, including linezolid (and also within 14 days after the end of their admission);
    - children's age (up to 14 years);
    - Suicidal tendencies, a propensity to abuse of psychoactive substances;
    - epilepsy, not amenable to adequate drug control;
    - pregnancy, lactation (during pregnancy and during breastfeeding, the application is only possible for life indications);
    - lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.
    Carefully:Caution should be used in patients with impaired renal function (KK 10-30 ml / min) and liver, with traumatic brain injury,in patients with shock or a change of consciousness of unknown origin, with increased intracranial pressure, with epileptic syndrome (central genesis) and an increased risk of seizures, with drug dependence on opioids (opioid addiction), against pain in the abdominal cavity of an unknown genesis ("acute stomach "), simultaneously taking selective serotonin reuptake inhibitors (some antidepressants and drugs that reduce appetite), tricyclic antidepressants, other tricyclic of the connections (e.g., promethazine), antimigraine drugs (triptans), narcotic analgesics, neuroleptics and other medications that reduce the threshold of convulsive readiness.
    Pregnancy and lactation:Tramadol contraindicated in pregnancy and during breastfeeding. Tramadol Adheres through the placental barrier. Long-term use of tramadol during pregnancy can lead to the development of the "cancellation" syndrome in a newborn. At pregnancy the preparation is admissible to apply only once.
    When applied immediately before or during labor tramadol does not affect the contractility of the uterus. The drug may cause a change in the respiratory rate in a newborn, which, however, usually has no clinical significance.
    About 0.1% of the dose of tramadol is excreted with the mother's milk during breastfeeding. After a single dose of tramadol, there is usually no need to interrupt breastfeeding. With long-term administration of tramadol, it is necessary to resolve the issue of stopping breastfeeding.
    Dosing and Administration:

    Tramadol is used according to the doctor's prescription, the dosage regimen is selected individually depending on the severity of the pain syndrome and the patient's sensitivity.

    In the absence of other regulations Tramadol should be given in the following doses:

    adults and adolescents over 14 years (more than 25 kg) - 1 tablet (50 mg), if necessary through 30-60 minutes you can take another pill; with severe pain, a single dose can be 100 mg (2 tablets). Tablets should be swallowed without chewing, squeezed with a small amount of liquid, or pre-dissolved in 1/2 cup of water, regardless of food intake.

    The daily dose should not exceed 400 mg (8 tablets).

    For the treatment of pain in cancer and severe pain in postoperative period higher doses may be used.

    In elderly patients (at the age of more than 75 years) due to the possibility of delayed excretion, the interval between administration of the drug can be increased in accordance with individual characteristics. In patients with kidney and liver disease tramadol may last longer. At CC <30 ml / min and in patients with hepatic insufficiency 12 hours interval between taking the next dose of the drug. It is possible to increase the interval between the administration of single doses. Do not prescribe the drug beyond the term justified from a therapeutic point of view. It is recommended that the patient be examined for the purpose of canceling therapy.

    Side effects:

    According to the World Health Organization (WHO), undesirable effects are classified according to their frequency of development as follows: very often (>1/10), often (from >1/100 to <1/10), infrequently (from >1 / 1,000 to <1/100), rarely (from >1 / 10,000 to <1 / 1,000), very rarely (<1 / 10,000); frequency is unknown - according to available data, it was not possible to establish the frequency of occurrence.

    Allergic reactions:

    rarely: itching of the skin, hives, rashes, including bullous, angioedema, bronchospasm, wheezing, anaphylaxis.

    From the side of the cardiovascular system:

    infrequently: tachycardia, orthostatic hypotension, palpitations,

    cardiovascular failure, collapse;

    rarely: fainting, bradycardia, increased blood pressure.

    From the digestive system:

    Often: nausea;

    often: dryness of the oral mucosa, vomiting, constipation;

    infrequently: a urge to vomit, diarrhea, irritation of the gastrointestinal tract, a feeling of heaviness in the stomach, bloating, dyspepsia;

    rarely: abdominal pain, difficulty in swallowing.

    From the central nervous system:

    Often: dizziness; often: headache, drowsiness;

    rarely: weakness, increased fatigue, paradoxical stimulation central nervous system (nervousness, agitation, anxiety, tremor, muscle spasms, euphoria, dysphoria, emotional lability, hallucinations), sleep disorders, sweating, confusion, disorders of coordination of motion, convulsions of central genesis (with intravenously in high doses or with simultaneous use of drugs that reduce the threshold convulsive

    preparedness), depression, amnesia, cognitive impairment and sensory perception (for example, the ability to make a decision, to realize problems), paresthesia, unsteadiness of gait, blurred vision, a violation of appetite, "nightmarish" dreams;

    frequency is unknown: speech disorders.

    From the skin:

    often: increased sweating;

    infrequently: urticaria, rash, including bullous, itching.

    From the side of the musculoskeletal system:

    rarely: muscle weakness.

    From the urinary system:

    rarely: different types of dysuria.

    Laboratory indicators:

    rarely: increased activity of "liver" transaminases.

    From the sense organs:

    rarely: impaired vision, taste;

    frequency is unknown: mydriasis.

    From the respiratory system:

    rarely: respiratory depression, dyspnea.

    Other:

    often: fatigue,

    rarely: violation of the menstrual cycle.

    Symptoms of the withdrawal reaction, similar to the response of opiate withdrawal: agitation, anxiety, increased excitability, sleep disturbance, hyperkinesia, tremor and symptoms of violations of the gastrointestinal tract.

    rarely: withdrawal symptoms: panic attack, strong excitability, hallucinations, parasthesia, tinnitus and unusual symptoms from the side central nervous system.

    Overdose:

    Symptoms: miosis, vomiting, collapse, oppression of consciousness, coma, convulsions, respiratory center depression, apnea.

    Treatment: ensuring airway patency, maintaining breathing and cardiovascular activity. Cramps, manifested in toxic doses, can be eliminated with diazepam. If breathing is disturbed, enter naloxone. Tramadol only to a small extent is excreted during dialysis, so the use of only hemodialysis or hemofiltration with acute intoxication with Tramadol is not enough.

    In case of an overdose, the patient should be under the supervision of a physician, treatment - symptomatic.

    When an overdose of the drug recommended gastric lavage and intake adsorbents (Activated carbon).

    Interaction:

    Contraindicated simultaneous use of tramadol and monoamine oxidase inhibitors (MAO inhibitors) (and two weeks after their withdrawal) due to the development of serious side effects from the central nervous system and the cardiovascular system.

    Strengthens the action ethanol and other agents that exert a depressing effect on the central nervous system. Joint application with naltrexone can reduce the analgesic effect. If necessary, the dose of tramadol can be increased. Inducers of microsomal liver enzymes (including carbamazepine, barbiturates) reduce the severity of the analgesic effect and the duration of action, increase the risk of seizures. Long-term use opioid analgesics and barbiturates stimulates the development of cross tolerance.

    Naloxone eliminates the effects of narcotic analgesics, including weakening respiratory depression and reduces analgesia.

    Quinidine increases the concentration of tramadol in the blood plasma and reduces the metabolite tramadol (mono-O-desmethyltramadol) due to competitive inhibition of the isoenzyme CYP2D6.

    Inhibitor inhibitors CYP3A4 (ketoconazole, erythromycin) inhibit the metabolism of tramadol (N-detylated) and active O-demethylated metabolite.

    Inhibitor inhibitors CYP2D6 (such as fluoxetine, paroxetine and amitriptyline) reduce the metabolism of tramadol.

    It is not recommended to combine tramadol from agonists-antagonists of opioid receptors (eg, buprenorphine, nalboufine, pentazocine), since the analgesic effect of tramadol, as a complete agonist of opioid receptors, can theoretically decrease.

    Simultaneous application with antagonists of 5-HTZ-serotonin receptors (ondansetron) increases the patient's need for tramadol in the treatment of postoperative pain.

    When used simultaneously with coumarin derivatives (warfarin), careful monitoring of patients is necessary, since in some of them the prothrombin time increases with the development of bleeding and subcutaneous hemorrhage.

    Selective serotonin reuptake inhibitors (citalopram, escitalopram, fluvoxamine, paroxetine, sertraline), some antidepressants and drugs that reduce appetite, tricyclic antidepressants, other tricyclic compounds (for example, promethazine), antimigraine drugs (triptans), narcotic analgesics, monoamine oxidase inhibitors, neuroleptics and other drugs that reduce the threshold of convulsive readiness, increase the risk of seizures and can cause serotonin syndrome (confusion, agitation, fever, increased sweating, ataxia, hyperreflexia, myoclonic cramps and diarrhea). The abolition of serotonergic drugs causes rapid relief of symptoms.

    Special instructions:
    Tramadol has a low potential for dependence formation. However, with its continued use, addiction, psychological and physical dependence may develop. Patients who are inclined to develop drug addiction or addiction should receive Tramadol only for a short period of time and under medical supervision. With prolonged use, it is possible to develop drug dependence. With a sharp discontinuation of Tramadol, development of the "withdrawal" syndrome is not ruled out.
    With increased time intervals apply Tramadol in elderly patients. Under careful medical supervision and in reduced doses should be used Tramadol against the background of the action of funds for anesthesia, sleeping pills and psychotropic drugs. It is forbidden to drink alcohol during treatment.
    Do not use to treat the syndrome of "withdrawal" of drugs. When using the drug Tramadol in the recommended doses, cases of seizures are noted. The administration of a dose exceeding the recommended daily dose of the drug (400 mg) increases the risk of seizures.
    The use of tramadol may increase the risk of seizures in patients taking drugs that reduce the threshold of convulsive readiness. Tramadol It is not applicable as a substitute therapy in patients with opioid dependence. Although tramadol is an agonist of opioid receptors, he can not stop the syndrome of "withdrawal" of opioids.
    The drug is not recommended for patients with severe intolerance of opioids of allergic and non-allergic origin.
    Effect on the ability to drive transp. cf. and fur:When using the drug Tramadol it is necessary to refrain from driving a car and practicing potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.
    Form release / dosage:
    Tablets 50 mg.

    Packaging:
    For 10 tablets per blister from A1 foil and OPA / AJ / PVC combination.
    For 1, 2, 3 or 5 blisters together with instructions for use in a cardboard box.
    Storage conditions:At a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:
    5 years.
    Do not use the drug after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:П N015731 / 01
    Date of registration:15.05.2009
    The owner of the registration certificate:HEXAL AG HEXAL AG Germany
    Manufacturer: & nbsp
    HEXAL AG Germany
    Representation: & nbspSANDOZ SANDOZ Switzerland
    Information update date: & nbsp17.09.2015
    Illustrated instructions
      Instructions
      Up